

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P26087	Application No. 10/511,274
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Ryozo NAGAI et al.	
		Filing Date I.A. Filed April 22, 2003	Group 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/N.H./	5 8 8 6 0 2 6	03/23/99	HUNTER et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/N.H./	6 1 - 0 2 2 0 4 7	01/30/86	JAPAN			
	6 1 - 0 7 6 4 4 0	04/18/86	JAPAN			
	9 7 / 1 1 0 6 1	03/27/97	W.I.P.O.			
	9 - 1 0 0 2 7 0	04/15/97	JAPAN			
	0 2 / 0 6 4 0 6 5	08/22/02	W.I.P.O.			
	9 5 / 0 3 0 3 6	02/02/95	W.I.P.O.			
	0 0 / 1 0 5 5 2	03/02/00	W.I.P.O.			
	0 1 / 3 4 1 3 2	05/17/01	W.I.P.O.			
	2 0 0 2 - 0 9 5 7 5 6	04/02/02	JAPAN			
	1 0 - 2 6 5 3 8 1	10/06/98	JAPAN			
	2 0 0 2 - 3 2 0 6 2 9	11/05/02	JAPAN			
	2 0 0 3 - 0 3 3 4 3 9	02/04/03	JAPAN			
/N.H./	2 0 0 3 - 0 9 3 5 2 0	04/02/03	JAPAN			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/N.H./	1	English Language Abstract of JP 61-022047.
	2	English Language Abstract of JP 61-076440
	3	English Language Abstract of JP 9-100270.
	4	English Language Abstract of JP 2002-095756.
	5	English Language Abstract of JP 10-265381.
	6	English Language Abstract of JP 2002-320629.
	7	English Language Abstract of JP 2003-033439.
	8	English Language Abstract of JP 2003-093520.
	9	SPORN et al., "Proliferative Diseases," The American Journal of Medicine, Vol. 70, pp. 1231-1236 (June 1981).
	10	MIANO et al., "Retinoids Versatile Biological Response Modifiers of Vascular Smooth Muscle Phenotype," Circulation Research, pp. 355-362 (2000).
/N.H./	11	NEUVILLE et al., "Retinoic Acid Regulates Arterial Smooth Muscle Cell Proliferation and Phenotypic Features In Vivo and In Vitro Through an RARα-Dependent Signaling Pathway," Arterioscler Tromb. Vascular Biology, pp. 1430-1436 (1999).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P26087	Application No. 10/511,274
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Ryozo NAGAI et al.	
		Filing Date I.A. Filed April 22, 2003	Group 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/N.H./	12	KAGECHIKA et al., "Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity," Journal of Medicinal Chemistry, Vol. 31, No. 11, pp. 2182-2192 (1988).
↓	13	EYROLLES et al., "Retinobenzoic Acids. 6. Retinoid Antagonists with a Heterocyclic Ring," Journal of Medicinal Chemistry, Vol. 37, No. 10, pp. 1508-1517 (1994).
↓	14	HIATT et al., "Drug-Eluting Stents for the Prevention of Restenosis: In Quest for the Holy Grail," Catheterization and Cardiovascular Intervention, Vol. 55, pp. 409-417 (2002).
↓	15	New England Journal of Medicine, Vol. 346, pp.1770-1771, and 1773-1780 (2002).
↓	16	HAXSEN et al., "Retinoids Inhibit the Actions of Angiotensin II on Vascular Smooth Muscle Cells," Circulation Research, Vol. 88, No. 6, pp. 637-644 (2001).
↓	17	MURAKAMI et al., "Inhibition of Angiogenesis and Intrahepatic Growth of Colon Cancer by TAC-101," Clinical Cancer Research, Vol. 5, No. 9, pp. 2304-2310 (1999).
↓	18	ZHOU et al., "Retinoid-dependent pathways suppress myocardial cell hypertrophy," Proceedings of the National Academy of Science of the United States of America, Vol. 92, No. 16, pp. 7391-7395 (1995).
↓	20	STREB et al., "Retinoids: Pleiotropic Agents of Therapy for Vascular Diseases?," Current Drug Targets-Cardiovascular and Haematological Disorders, Vol. 3, No. 1, pp. 31-57 (2003).
/N.H./	21	SHINDO et al., "Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling," Nature Medicine, Vol. 8, No. 8, pp. 856-863 (2002).

EXAMINER /Nannette Holloman/ (02/15/2008)

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.